The first human trial of cell reprogramming starts this month — and it begins with the eye
A small biotech company is about to test whether ageing cells can literally be ‘rewound’ in living humans. If it works in the eye, it could change medicine forever.
Life Biosciences has received approval to test a cellular reprogramming therapy in people with age-related vision loss, with enrollment expected as early as this month. The approach draws on Nobel Prize-winning work by Shinya Yamanaka, who discovered that a set of proteins — now called Yamanaka factors — can coax adult cells into behaving like younger ones. In animal studies involving mice and primates, partial versions of this technique have already reversed some vision loss. Now comes the first real test in humans.
The eye is a deliberate choice, not a random starting point. It is a relatively contained organ, meaning therapies can be delivered locally without affecting the rest of the body. Results are also measurable: visual acuity, retinal function, cellular health. If the biological age of eye cells can genuinely be rolled back, it would mark the first time such a thing has been demonstrated in human beings. Crucially, the aim is not to treat one specific disease — it is to address ageing itself as an underlying driver of decline.
Why the FDA kept saying no — and what may be shifting
The US Food and Drug Administration has long refused to classify ageing as a disease. That matters enormously for drug approval: any therapy must demonstrate it treats a recognised medical condition, not that it ‘slows ageing’. Life Biosciences navigates this by framing the trial around age-related eye conditions as its primary target, with rejuvenation as the mechanism rather than the official claim. It is a regulatory workaround — but also a strategic one. If the trial succeeds, it becomes increasingly hard for the FDA to insist that ageing cannot be a medical target.
The longevity field is watching closely, and not just because the science looks promising. Approval of this class of therapy would set a regulatory precedent, potentially opening the door for dozens of similar programmes currently waiting on permission or funding. At the same time, the risks are real: uncontrolled cell reprogramming can trigger tumour formation. Whether the safety profile seen in animals holds up in humans is precisely what this first phase is designed to determine.
What ‘reversing biological age’ actually involves
Reprogramming works through epigenetic changes — alterations in how genes are switched on or off, without changing the underlying DNA sequence. As cells age, they accumulate chemical ‘tags’ that disrupt normal function. Yamanaka factors can erase some of these tags, causing cells to function more like their younger selves. But running the full reprogramming process causes cells to lose their identity entirely — a liver cell stops being a liver cell. The challenge is partial reprogramming: resetting cells just enough without stripping away their function. Finding that balance is arguably the hardest unsolved problem in this field.
Whether this trial marks a genuine turning point in how regulators think about ageing, or remains a narrow exception for one specific eye condition, is a question no one can answer yet with any confidence.